← Back to All Filings

Charles River Laboratories CFO Purchases 10 Shares via ESPP

Low SignificanceOctober 2, 2026 at 5:24:21 PM EDT

Subscribe to track CRL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

### Insider Purchase Alert: Charles River Laboratories International, Inc. (NYSE: CRL)

**Insider:** Glenn Coleman
**Title:** EVP & Chief Financial Officer
**Transaction Date:** September 30, 2026
**Filing Date:** October 2, 2026

**Transaction Summary:**
- **Action:** Open Market / Plan Purchase (ESPP)
- **Shares:** 10 shares
- **Price:** $297.43 per share
- **Total Consideration:** $2,974.30
- **Post-Transaction Holdings:** 27,762 shares (Direct)

*Significance:* Low (Routine acquisition via Employee Stock Purchase Plan)

Comprehensive Analysis

Insider Transaction Overview

On September 30, 2026, Glenn Coleman, Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. (CRL), acquired 10 shares of common stock at a price of $297.43 per share. The transaction amounted to a total consideration of approximately $2,974.30.

Transaction Details and Context

  • Transaction Code: P (Purchase)
  • Nature of Acquisition: As indicated in the footnotes, the shares were acquired under the company's Employee Stock Purchase Plan (ESPP) at fair market value, following an election made during an open trading window prior to the purchase period.
  • Direct Holdings Post-Transaction: 27,762 shares.
  • Significance Assessment: Low. ESPP purchases are programmatic, recurring, and typically small in volume, carrying minimal informational signal compared to discretionary open-market insider purchases.
Topics:#CRL#InsiderTrading#CharlesRiver#SECForm4#ESPP

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.